
Kluwer Patent Blog

Patent case: Teva Pharmaceuticals USA, Inc. v. Sandoz Inc., USA

Brian Craig (Wolters Kluwer Legal & Regulatory US) · Thursday, October 18th, 2018

Concluding that the asserted claims of patents relating to dosing and administration of the drug Copaxone used to treat multiple sclerosis are obvious, the U.S. Court of Appeals the Federal Circuit has affirmed a decision by the federal district court in Delaware invalidating the patents, handing a major victory to generic drug manufacturers. The Federal Circuit found the district court committed no error in construing claim terms as non-limiting for nonobviousness purposes or in invalidating as obvious all asserted claims of the Copaxone patents, including a 40-milligram dosage three times per week (Teva Pharmaceuticals USA, Inc. v. Sandoz Inc., October 12, 2018, Reyna, J.).

Case date: 12 October 2018

Case number: No. 2017-1575

Court: United States Court of Appeals, Federal Circuit

A full summary of this case has been published on [Kluwer IP Law](#).

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer
Leading change

This entry was posted on Thursday, October 18th, 2018 at 4:49 am and is filed under [Case Law](#), [Pharma](#), [Pharmaceutical patent](#), [United States of America](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.